Jefferson University Hospitals

Provider Profile

Edith Mitchell, MD, FACP

Jefferson University Physician

Academic Title: Clinical Professor
Director, Center to Eliminate Cancer Disparities
Program Leader, Gastrointestinal Oncology

Medical Oncology
Medical Oncology - Colorectal Cancer
Medical Oncology - Esophageal Cancer
Medical Oncology - Gastrointestinal (GI) Cancer
Medical Oncology - Liver Cancer
Medical Oncology - Pancreatic Cancer
Medical Oncology - Stomach Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

925 Chestnut Street
Suite 320A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 503-7697

Medical Services

Years in Practice


Board Certifications

  • Medical Oncology
  • Internal Medicine

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital


  • Medical College of Virginia, Medical School


  • Meharry Medical College


  • Meharry Medical College


  • Georgetown University Hospital, DC

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Insurances Accepted

  • Aetna
  • Aetna PA Employee Benefit Trust Fund (PEBTF)
  • Amer Assoc Retired Persons (AARP)
  • AmeriHealth
  • Amerihealth Caritas
  • AmeriHealth Comprehensive
  • AmeriHealth HMO
  • AmeriHealth Major Medical
  • AmeriHealth Personal Choice
  • BC BS Special Care
  • Blue Choice
  • Blue Cross/Blue Shield
  • Blue Cross/Blue Shield of Delaware
  • Cigna Healthspring
  • Cigna PPO, POS
  • Consumer Health Network PPO
  • CorVel
  • Coventry/Health America
  • Delaware Blue Cross/Blue Shield
  • Devon
  • Empire BC/BS
  • Employers Health Network PPO
  • Evolutions (Guardian Resources)
  • Federal BCBS
  • First Health Network
  • Galaxy
  • Geisinger Health Plan
  • Health America PPO
  • Health Management Network PPO
  • Horizon Blue Cross/Blue Shield
  • Horizon HMO
  • HumanaChoicePPO,Medicare,GoldPlusHMO
  • Inter-County Health Plan
  • Intergroup Preferred
  • Jeff Plus
  • Keystone 65 HMO
  • Keystone First VIP Choice
  • Keystone First/Connect
  • Keystone Health Plan East
  • Medallion of New Jersey
  • Medicaid of PA
  • Medicare
  • Mercy LIFE
  • MultiPlan Inc.
  • NJ Blue Shield
  • NJ Plus
  • Oxford of PA
  • Personal Choice (GPPPN)
  • Personal Choice 65
  • PlanCare America
  • Postal Workers/Mailhandlers
  • PPO Next
  • Preferred Care PPO
  • Premier Blue
  • Prime Health Services, Inc.
  • Private Healthcare Systems (PHCS)
  • Qualcare
  • Tricare
  • United Healthcare
  • UPMC HMO,PPO ReadingHspEmpONLY
  • UPMC Medicare HMO
  • US Family Health Plan

Recent Publications

American Society of Clinical Oncology strategic plan for increasing racial and ethnic diversity in the oncology workforce

Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: A phase II Eastern cooperative oncology group-American college of radiology imaging network cancer research group trial (E3205)

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials

Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms

African American Patients’ Psychosocial Support Needs and Barriers to Treatment: Patient Needs Assessment

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy

Moonshot Toward a Cure for Cancer

Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism

Positive association of fibroadenomatoid change with HER2-negative invasive breast cancer: A co-occurrence study

5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: A randomized Phase IIb study

Efficacy endpoints of radiation therapy group protocol 0247: A randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer

Determinants of pain severity changes in ambulatory patients with cancer: An analysis from eastern cooperative oncology group trial E2Z02

Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA

Consistent Surgeon Evaluations of Three-Dimensional Rendering of PET/CT Scans of the Abdomen of a Patient with a Ductal Pancreatic Mass

Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer